What interviewers actually evaluate

AbbVie sales interviews test whether candidates understand how specialty pharmaceutical selling across a portfolio spanning biologic immunology, oncology, and medical aesthetics creates distinct sales models that differ fundamentally from each other – where Skyrizi and Rinvoq selling in rheumatology requires sales professionals who can engage rheumatologists in evidence-based conversations about IL-23 inhibitor and JAK inhibitor mechanism of action, clinical trial data, and head-to-head comparisons with Stelara, Tremfya, Taltz, and other competing biologics in a specialty where physicians make treatment decisions based on clinical evidence rather than relationship alone, where Rinvoq selling across its seven approved indications requires indication-specific selling approaches because the rheumatologist who prescribes Rinvoq for rheumatoid arthritis is evaluating different patient profiles and competitive alternatives than the dermatologist prescribing for atopic dermatitis or the gastroenterologist prescribing for Crohn's disease, where Botox Cosmetic selling to physician injectors through Allergan Aesthetics requires a practice development selling model that helps injectors build their aesthetic medicine practice revenue rather than the clinical evidence selling model that drives prescription biologic territory management, and where managed care access selling to pharmacy benefit managers and health plan formulary committees requires account executives who can build the clinical economic value proposition for Skyrizi and Rinvoq preferred formulary status against competing biologics whose manufacturers are offering competitive rebates to win the same formulary tier. Sales at AbbVie spans Skyrizi and Rinvoq specialty biologic territory management in rheumatology and dermatology (where building prescribing behavior for a JAK inhibitor with a boxed warning requires sales professionals who can address prescriber concerns about Rinvoq's cardiovascular and malignancy risk profile through evidence-based clinical conversations that present the benefit-risk in context for specific patient populations), multi-indication selling as Skyrizi and Rinvoq expand into gastroenterology (where entering a therapeutic area where AbbVie has historically had limited commercial presence requires building new physician relationships with gastroenterologists who are already prescribing established biologics from Janssen, Takeda, and other competitors), managed care and formulary access selling (where developing preferred formulary placement for Skyrizi and Rinvoq in commercial and Medicare Part D plans requires sales account executives who can present health economic evidence and negotiate contracting terms that make AbbVie's biologics competitive against Humira biosimilars and other specialty medications), and Botox Cosmetic aesthetic sales to physician injectors (where building an injector's Botox Cosmetic and Juvederm practice revenue through the Alle loyalty program, Allergan Medical Institute training, and patient-facing materials requires selling skills centered on practice economics and patient acquisition rather than clinical prescribing behavior change).

Start your free AbbVie Sales practice session.

What interviewers actually evaluate

Skyrizi and Rinvoq Specialty Biologic Selling, Managed Care Access Navigation, and Botox Aesthetic Practice Development

AbbVie sales interviews probe whether candidates understand how specialty pharmaceutical selling differs from general pharmaceutical or device selling in the clinical evidence engagement requirement (a Rinvoq territory manager who calls on a rheumatologist must be able to discuss the SELECT clinical trial program's efficacy data across RA, PsA, and axSpA, explain the JAK inhibitor class boxed warning context and the patient populations where the risk-benefit calculation favors Rinvoq, and respond to the physician's specific question about whether Rinvoq's malignancy risk data differs meaningfully from Pfizer's tofacitinib – sales professionals who engage in this level of clinical depth are differentiated from those who present slides without being able to answer physician questions), the managed care access navigation complexity (Skyrizi and Rinvoq's commercial success depends not just on physician prescribing intent but on patients' ability to access therapy through their insurance, and sales representatives who understand their territory's formulary landscape for each product, know which payers require step therapy and which do not, and can help physicians identify covered patient populations will drive higher conversion of prescribing intent to actual new patient starts than those who leave access navigation to the physician's office staff), and the multi-indication selling challenge (each new Skyrizi or Rinvoq indication requires building prescribing behavior in a physician specialty that may have different relationship dynamics, different evidence evaluation criteria, and different patient populations than the indication where AbbVie's initial prescribing relationships were built – and sales professionals who can adapt their clinical selling model to the gastroenterologist who evaluates IBD biologics differently than the rheumatologist evaluates RA biologics will build prescribing behavior in new specialties more efficiently).

The Botox Cosmetic selling dimension requires understanding that Allergan Aesthetics' sales model for physician injectors is fundamentally different from AbbVie's biopharmaceuticals selling – focused on practice development, patient acquisition support, treatment frequency, and the business economics of an aesthetic medicine practice rather than clinical evidence for a specific patient population.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
Skyrizi and Rinvoq specialty biologic selling to immunology physicians	Do you understand how to build prescribing behavior for Skyrizi in a competitive dermatology territory where the rheumatologist and dermatologist you are calling on already prescribe Stelara and Tremfya – how to identify the physician's current prescribing patterns and patient segments where Skyrizi's clinical differentiation is most compelling, what the clinical evidence presentation looks like for comparing Skyrizi's VOYAGE 1 and 2 data against competing IL-23 inhibitors, and how to address the physician's question about whether Skyrizi's psoriasis clearance rates justify a formulary-driven prescribing change for their current biologic-experienced patients? We flag sales answers that describe biologic selling as product feature presentation without engaging with the clinical evidence positioning and competitive differentiation that specialty biologic selling requires.	Skyrizi clinical differentiation positioning against Stelara and Tremfya for biologic-experienced psoriasis patients, VOYAGE clinical trial data presentation for IL-23 inhibitor prescribing conversion, formulary access and step therapy navigation for commercial psoriasis patient coverage
Managed care formulary access navigation and prior authorization support for specialty biologics	Can you describe how to support a gastroenterologist who wants to prescribe Skyrizi for a Crohn's disease patient but is concerned about prior authorization barriers – how to assess the specific commercial insurer's step therapy requirements for IL-23 inhibitors in Crohn's disease, what the peer-to-peer review support process looks like when the initial prior authorization is denied, and how to use AbbVie's myAbbVie Assist hub services to provide bridge supply while the authorization appeal is processed? We score whether your managed care selling approach engages with the insurance access navigation and hub services coordination that determine whether a physician's Skyrizi prescribing intention translates into a patient actually receiving the drug.	Commercial insurer step therapy requirement assessment for Skyrizi Crohn's disease prior authorization, peer-to-peer review coordination support for initial prior authorization denial appeals, myAbbVie Assist bridge supply management for authorization pending patients
Humira account management and physician transition to Skyrizi and Rinvoq	Do you understand how to manage the physician relationship transition from Humira prescribing to Skyrizi or Rinvoq prescribing – how to identify which of a rheumatologist's current Humira patients in rheumatoid arthritis have clinical profiles that would support a transition to Rinvoq based on disease control status, payer coverage, and patient preference, what the clinical conversation looks like for presenting Rinvoq's different mechanism of action and efficacy profile to a physician who has had good outcomes with Humira, and how to navigate the physician's concern that changing their stable Humira patients to a new biologic creates clinical risk without clear benefit? We detect sales answers that describe Humira account management as simply managing a declining product without engaging with the proactive patient transition strategy that optimizes the account relationship for AbbVie's overall portfolio.	Current Humira patient clinical profile assessment for Rinvoq transition candidacy identification, Rinvoq mechanism and efficacy clinical conversation framework for Humira-prescribing rheumatologists, stable patient transition risk management objection handling
Botox Cosmetic aesthetic sales to physician injectors and practice development	Can you describe how to develop a physician injector's Botox Cosmetic and Juvederm practice revenue – how to assess a dermatologist or plastic surgeon's current aesthetic patient volume, treatment frequency, and revenue per patient to identify where Allergan Aesthetics' training programs, Alle loyalty platform, and patient marketing materials can increase practice profitability, what the practice development conversation looks like for introducing a physician to Allergan Medical Institute training programs that build their injector skill and patient confidence, and how to convert an injector who currently uses competing neuromodulators to Botox Cosmetic as their primary treatment choice for aesthetic patients? We flag sales answers that describe aesthetic sales as product specification selling without engaging with the practice development and patient acquisition economics that distinguish Botox Cosmetic selling from prescription biologic territory management.	Physician injector aesthetic practice revenue assessment for Botox Cosmetic and Juvederm practice development opportunity, Allergan Medical Institute training program introduction for injector skill and patient confidence building, neuromodulator competitive conversion strategy for Botox Cosmetic preferred product adoption

How a session works

Step 1: Choose an AbbVie sales scenario – Skyrizi and Rinvoq specialty biologic territory management in rheumatology or dermatology, managed care formulary access navigation and prior authorization support, Humira account management and physician transition to successor products, or Botox Cosmetic aesthetic practice development selling.

Step 2: The AI interviewer asks realistic AbbVie sales questions: how you would approach a new rheumatologist territory call where the physician has previously prescribed Humira but has not yet started any patients on Rinvoq despite its RA approval three years ago, including what your pre-call planning looks like, what your opening conversation covers, and how you identify the specific patient segment in her practice where Rinvoq's clinical profile would be most differentiated; how you would manage a commercial account conversation with a pharmacy benefit manager who is evaluating whether to place Skyrizi on preferred formulary for commercial members with psoriasis, including what clinical economic evidence you present, how you structure the contracting conversation, and how you position Skyrizi against Tremfya and Taltz on a total cost basis; or how you would build a new Botox Cosmetic injector relationship with a dermatologist who has 60% of their practice in medical dermatology but is interested in expanding into aesthetic medicine.

Step 3: You respond as you would in the actual interview. The system scores your answer on specialty biologic clinical selling, managed care access navigation, Humira account transition, and Botox aesthetic practice development.

Step 4: You get sentence-level feedback on what demonstrated genuine AbbVie specialty pharmaceutical sales expertise and what needs stronger clinical evidence positioning specificity or managed care access navigation detail.

Frequently Asked Questions

How does selling Skyrizi differ from selling Humira?
Skyrizi is an IL-23 inhibitor with a different mechanism of action from Humira's TNF inhibition, which means the clinical selling story emphasizes different aspects of immune pathology and a different patient profile. Skyrizi was developed specifically to address the IL-23-driven pathway, and its clinical data in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis demonstrates long-term remission rates that require a clinical conversation about mechanism and durability rather than simply about switching products. Unlike Humira selling during its growth phase, Skyrizi selling involves competitive positioning against other IL-23 inhibitors and explaining why an IL-23 inhibitor might be preferred over a JAK inhibitor for specific patients, requiring deeper immunology knowledge than typical biologic sales.

What makes Rinvoq selling more complex given its boxed warning?
Rinvoq carries an FDA-mandated boxed warning for the JAK inhibitor class regarding serious cardiovascular events, malignancy, mortality, and thrombosis. This means that every Rinvoq selling conversation must be prepared to discuss the boxed warning in the context of Rinvoq's specific clinical data and the patient populations where the risk-benefit calculation supports prescribing. Sales representatives who can present Rinvoq's benefit-risk profile in a nuanced way – acknowledging the class warning while presenting the specific evidence for patient populations where Rinvoq offers meaningful clinical benefit – are more credible with prescribers than those who either avoid the safety topic or present it without clinical context. Managed care access for Rinvoq in some plans also reflects the boxed warning through additional prior authorization criteria.

How does the Botox Cosmetic sales model differ from specialty biologic selling?
Botox Cosmetic selling through Allergan Aesthetics is a practice development model rather than a clinical evidence model. Physician injectors are not making prescribing decisions based on clinical trial data for their patients' medical conditions; they are building a business that generates revenue from aesthetic treatments. Allergan Aesthetics' sales model supports injectors with training programs through Allergan Medical Institute that improve their technique and patient confidence, the Alle loyalty program that creates patient retention and repeat visits, and patient acquisition marketing materials that help injectors attract new aesthetic patients. Commercial success measures for Botox Cosmetic selling include practice treatment volume, vial utilization, and injector retention rather than new patient starts and persistency measures that apply to prescription biologic selling.

How does AbbVie's managed care access selling work?
AbbVie's managed care access organization calls on pharmacy benefit managers, commercial health plans, and Medicare Part D plans to achieve preferred formulary placement for Skyrizi and Rinvoq. The managed care selling process involves presenting clinical economic analyses showing the total cost of care benefits of effective biologic therapy, negotiating rebate contracts that position AbbVie's products competitively on formulary tiers, and developing access solutions that minimize prior authorization barriers for physician prescribing. Formulary placement decisions directly affect the commercial success of Skyrizi and Rinvoq because preferred formulary status reduces patient out-of-pocket costs, minimizes step therapy requirements, and increases prescriber willingness to prescribe when they know their patients can access the therapy.

How does AbbVie structure its specialty pharmaceutical sales organization?
AbbVie organizes its specialty pharmaceutical sales organization by therapeutic area to enable the development of deep specialty-specific selling expertise. Immunology representatives call on rheumatologists and dermatologists for Skyrizi and Rinvoq, requiring clinical knowledge of inflammatory disease management. Gastroenterology representatives call on gastroenterologists for Skyrizi and Rinvoq in Crohn's and ulcerative colitis indications. Oncology representatives manage Imbruvica and Venclexta selling to hematology-oncologists in a therapeutic area with different commercial dynamics than immunology. Allergan Aesthetics maintains a separate sales organization for Botox Cosmetic and Juvederm selling to physician injectors. This therapeutic area organization allows each sales force to develop the clinical expertise and specialty physician relationships that their customers require.